在第四阶段高度血清性卵巢癌中使用新辅助药 pembrolizumab:第二阶段 Neo-Pembro 试验
S L Aronson1,2, B Thijssen3,4, M Lopez-Yurda5
1Department of Medical Oncology, The Netherlands Cancer Institute, Amsterdam, the Netherlands.
Nature communications
|April 14, 2025
概括
在高度血清性卵巢癌 (HGSOC) 中,在化疗中添加 pembrolizumab 显示出有前途的结果. 在27%的患者中观察到主要的病理反应,并确定了长期生存益处和潜在的生物标志物.
科学领域:
- 在瘤学瘤学.
- 免疫学 免疫学 免疫学
- 遗传学 是一个遗传学.
背景情况:
- 免疫检查点抑制剂 (ICI) 在高度血清性卵巢癌 (HGSOC) 中显示出有限的疗效.
- 了解影响HGSOCICI反应的因素对于改善治疗结果至关重要.
- 识别预测生物标志物可以指导患者选择免疫治疗.
研究的目的:
- 评估新辅助剂布罗利祖马布与化疗联合对未经治疗的IV期HGSOC免疫激活的影响.
- 评估病理反应率及其与临床结果的关联.
- 为了确定潜在的生物标志物,预测HGSOC中对 pembrolizumab的反应.
主要方法:
- 第二阶段临床试验 (Neo-Pembro研究) 涉及33名未经治疗的IV期HGSOC患者.
- 组合疗法:卡博普拉丁-帕克利塔塞尔化学疗法与新辅助剂pembrolizumab.
- 通过多重免疫光和基因表达分析评估内免疫激活.
- 评估病理反应,整体存活率 (OS),无进展生存率 (PFS) 和循环瘤DNA (ctDNA) 清除.
主要成果:
- 观察到显著的免疫激活,包括增加的CD8+T细胞和增强的TNF-α和干扰素-γ信号传递.
- 在27%的患者 (9/33) 中实现了主要的病理反应,与免疫激活和改善的生存状况密切相关.
- 主要响应者表现出高的长期生存率和无复发生存率.
- 在所有主要响应者中观察到ctDNA清除,与长期PFS和OS相关.
- 确定PD-L1表达和同源重组缺陷 (HRD) 是主要反应的潜在预测生物标志物.
结论:
- 新辅助药 pembrolizumab与化疗结合使用是耐受良好,并诱导显著的免疫激活在HGSOC.
- 主要病理反应与有利的长期临床结果和ctDNA清除有关.
- PD-L1表达和HRD可以作为有价值的生物标志物来识别可能受益于新辅助 pembrolizumab HGSOC 患者.
相关概念视频
Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
Treatment Resistant Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
Treatment Resistent Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Clinical Trials
Clinical trials are prospective experimental studies conducted on humans to determine the safety and efficacy of treatments, drugs, diet methods, and medical devices. Using statistics in clinical trials enables researchers to derive reasonable and accurate conclusions from the collected data, allowing them to make wise decisions in uncertain situations. In medical research, statistical methods are crucial for preventing errors and bias.
There are four phases in a clinical trial. A phase one...
There are four phases in a clinical trial. A phase one...
Clinical Trials: Overview
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...


